Evaluation of Serum Oncostatin M in Inflammatory Bowel Disease Patients. | ||
| Minia Journal of Medical Research | ||
| Articles in Press, Accepted Manuscript, Available Online from 30 October 2025 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mjmr.2025.431868.2107 | ||
| Authors | ||
| Asmaa hassanien Mehany* 1; hatem ahmed1; mostafa ahmed elsayed abuelela2; Yehia Zakaryia Mahmoud1 | ||
| 1Internal Medicine department, Faculty of Medicine, Minia University, Minia, Egypt. | ||
| 2clinical pathology , faculty of medicine , minia university | ||
| Abstract | ||
| Background: The exact etiology of IBD remains unclear, but it is believed to involve a complex interaction between genetic susceptibility, environmental factors, the intestinal microbiota and immune dysregulation. Oncostatin M is an emerging biomarker of the interleukin 6 family produced by activated T cells, monocytes and macrophages and is known to mediate various biological functions in the intestinal inflamed tissues. Aim of the work: to evaluate the role of serum Oncostatin M in IBD patients. Methods: This cross-sectional study was conducted at inpatient and outpatient IBD clinic of hepatogastroentrology hospital, Minia University on 85 participants from November (2023) to November (2024). The study participants were divided into three groups. Group I: Cases (N=45) IBD patients subdivided according to severity by histopathological examination into; IA: mild cases (N= 17), IB: moderate to severe cases (N= 28). Group II: Irritable bowel syndrome (N= 20) patients. Group III: Healthy control (N=20) participants. Results: The results demonstrated that serum OSM levels were significantly higher in IBD patients compared to both IBS patients and healthy controls (p<.001). ESR and CRP levels were significantly higher in IBD patients Compared to IBS and healthy control (p<.001). Fecal calprotectin was significantly higher in moderate to severe group of IBD patients than mild group (p<.001). Conclusion: We concluded that IBD patients had significantly higher levels of serum Oncostatin M, CRP and ESR compared to IBS patients and healthy controls. In addition, fecal calprotectin was significantly higher levels in moderate to severe group of IBD patients than mild group. | ||
| Keywords | ||
| Inflammatory Bowel Disease (IBD); Oncostatin M (OSM); Crohn’s Disease | ||
|
Statistics Article View: 1 |
||
